Kiadis Pharma is a biopharmaceutical company focused specifically on complications and limitations of bone marrow transplantations in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients and address high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada.

With leading oncologists participating in our clinical programs, an ongoing external validation of Kiadis Pharma’s technologies and products is ensured.

The drive to accomplish the strategic growth of Kiadis Pharma as a Dutch-Canadian enterprise is endorsed by our investors, academic partners and a cross-Atlantic management team, uniting all expertise to bring products to market.